Drug Profile
Breast cancer vaccine HER-2/neu - GSK
Alternative Names: HER-2/neu peptide vaccine - GSKLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 13 Sep 2004 Corixa and GlaxoSmithKline have initiated a phase I trial for Breast cancer in USA
- 31 Dec 2003 Discontinued - Phase-I for Lung cancer in USA (unspecified route)
- 31 Dec 2003 Discontinued - Phase-I for Ovarian cancer in USA (unspecified route)